Trial reportLipids2010
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
Trial report in Lipids, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.The Journal of clinical endocrinology and metabolism · 2012Guideline
- A diethylene glycol oligomer squalene derivative modulates metabolic gene expression in ob/ob mice.EXCLI journal · 2026Article
- Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.Journal of clinical medicine · 2021Review
- Current Diagnosis and Management of Primary Chylomicronemia.Journal of atherosclerosis and thrombosis · 2021Review
- ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.Current atherosclerosis reports · 2021Review
- Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Biomedical reports · 2018Article
- Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.Digestive diseases and sciences · 2016Review
- Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters.Lipids in health and disease · 2014Article
- Article
- A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.Cardiovascular drugs and therapy · 2012 · on this mapReview
- Role of ezetimibe in non-alcoholic fatty liver disease.World journal of hepatology · 2011Article
- Clinical applications of advanced lipoprotein testing in diabetes mellitus.Clinical lipidology · 2011Article
- Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
- Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.